Kardiologie 2007

Was ist neu?

• Stabile koronare Herzerkrankung: Koronarinterventionen auf dem Prüfstand

• Medikamenten-freisetzende Stents: Restenose- versus Thromboserate

• In-Stent-Restenose: Kommt der Medikamenten-beschichtete Ballon?

• Vorhofflimmern: Ablation gewinnt an Bedeutung

• Dekompensierte Herzinsuffizienz: Neue Substanzen können Sterblichkeit nicht senken

• Laienreanimation: Ohne Beatmung günstiger

Literatur

• 1 Nagao K. for the SOS-KANTO study group . Cardiopulmonary resuscitation by bystanders with chest compression only (SOS-KANTO): an observational study.  Lancet. 2007;  369 920-926
• 2 Boden W E, O’Rourke R A, Teo K K. et al . Optimal medical therapy with or without PCI for stable coronary disease.  N Engl J Med. 2007;  356 1503-1516
• 3 Eisenstein E L, Anstrom K J, Kong D F. et al . Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.  JAMA. 2007;  297 159-168
• 4 Fuster V, Ryden L E, Cannom D S. et al . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines.  Eur Heart J. 2006;  27 1979-2030
• 5 Gheorghiade M. et al . Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.  JAMA. 2007;  297 1332-1343
• 6 Holmes D R, Teirstein P, Satler L. et al . Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.  JAMA. 2006;  295 1264-1273
• 7 Kastrati A, Mehilli J, Pache J. et al . Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.  N Engl J Med. 2007;  356 1030-1039
• 8 Konstam M A, Gheorghiade M, Burnett J C. et al . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.  JAMA. 2007;  297 1319-1331
• 9 Lagerqvist B, James S K, Stenestrand U. et al . Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.  N Engl J Med. 2007;  356 1009-1019
• 10 Mauri L, Hsieh W H, Massaro J M. et al . Stent thrombosis in randomized clinical trials of drug-eluting stents.  N Engl J Med. 2007;  356 1020-1029
• 11 Mebazaa A, Nieminen M S, Packer M. et al . Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial.  JAMA. 2007;  297 1883-1891
• 12 Morice M C, Colombo A, Meier B. et al . Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.  JAMA. 2006;  295 895-904
• 13 Oral H. et al . Circumferential pulmonary-vein ablation for chronic atrial fibrillation.  N Engl J Med. 2006;  354 934-941
• 14 Scheller B, Hehrlein C, Bocksch W. et al . Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.  N Engl J Med. 2006;  355 2113-2124
• 15 Stone G W, Ellis S G, O’Shaughnessy C D. et al . Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.  JAMA. 2006;  295 1253-1263
• 16 Stone G W, Moses J W. et al . Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.  N Engl J Med. 2007;  356 998-1008